Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedFeb 27, 2026
DataAggregated Company Financials
Companies15
  • 7D-1.9%
  • 3M10.5%
  • 1Y26.2%
  • YTD12.1%

Over the last 7 days, the Pharma industry has dropped 1.9%, driven by declines in AstraZeneca and GSK of 1.2% and 2.7%, respectively. In contrast, Allergy Therapeutics has gained 20%. Over the past 12 months, the industry was up 26%. Looking forward, earnings are forecast to grow by 9.2% annually.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 27 Feb 2026UK£361.7bUK£90.2bUK£15.6b22.5x23.2x4x
Sun, 25 Jan 2026UK£322.4bUK£88.8bUK£14.5b22.2x22.2x3.6x
Tue, 23 Dec 2025UK£322.5bUK£89.4bUK£14.6b21.7x22.1x3.6x
Thu, 20 Nov 2025UK£320.4bUK£90.7bUK£14.8b21.4x21.6x3.5x
Sat, 18 Oct 2025UK£293.5bUK£87.7bUK£11.7b20.6x25.1x3.3x
Mon, 15 Sep 2025UK£282.1bUK£87.3bUK£11.7b21.2x24.2x3.2x
Wed, 13 Aug 2025UK£266.3bUK£87.5bUK£11.7b21.1x22.8x3x
Fri, 11 Jul 2025UK£263.8bUK£86.2bUK£10.6b27.8x24.9x3.1x
Sun, 08 Jun 2025UK£271.9bUK£86.3bUK£10.6b27.2x25.6x3.1x
Tue, 06 May 2025UK£268.3bUK£87.4bUK£10.7b26.7x25x3.1x
Thu, 03 Apr 2025UK£274.5bUK£87.5bUK£9.7b32.1x28.3x3.1x
Sat, 01 Mar 2025UK£288.7bUK£88.9bUK£9.8b29.1x29.6x3.2x
Mon, 27 Jan 2025UK£234.4bUK£75.6bUK£7.8b32.9x30x3.1x
Wed, 25 Dec 2024UK£223.9bUK£75.5bUK£7.8b31.1x28.7x3x
Fri, 22 Nov 2024UK£216.9bUK£75.3bUK£7.8b30.3x27.9x2.9x
Sun, 20 Oct 2024UK£253.4bUK£72.3bUK£9.0b30.9x28x3.5x
Tue, 17 Sep 2024UK£260.2bUK£71.8bUK£9.0b38.2x29x3.6x
Thu, 15 Aug 2024UK£273.3bUK£73.0bUK£9.1b39.8x30x3.7x
Sat, 13 Jul 2024UK£259.5bUK£70.7bUK£9.4b32.7x27.5x3.7x
Mon, 10 Jun 2024UK£268.8bUK£71.5bUK£9.6b30.5x28.1x3.8x
Wed, 08 May 2024UK£267.5bUK£72.2bUK£9.6b32.6x27.8x3.7x
Fri, 05 Apr 2024UK£242.9bUK£70.8bUK£9.7b31.9x25x3.4x
Sun, 03 Mar 2024UK£233.3bUK£70.7bUK£9.7b30.9x23.9x3.3x
Tue, 30 Jan 2024UK£237.5bUK£68.9bUK£10.7b35.9x22.3x3.4x
Thu, 28 Dec 2023UK£233.7bUK£68.6bUK£10.6b35.4x22x3.4x
Sat, 25 Nov 2023UK£227.1bUK£69.2bUK£10.7b53x21.2x3.3x
Mon, 23 Oct 2023UK£234.8bUK£70.7bUK£10.4b53.5x22.7x3.3x
Wed, 20 Sep 2023UK£240.0bUK£70.0bUK£10.3b53.5x23.3x3.4x
Fri, 18 Aug 2023UK£236.6bUK£68.9bUK£10.1b53.5x23.3x3.4x
Sun, 16 Jul 2023UK£226.8bUK£66.7bUK£7.8b54.3x29.2x3.4x
Tue, 13 Jun 2023UK£252.4bUK£68.4bUK£8.0b55.4x31.7x3.7x
Thu, 11 May 2023UK£254.9bUK£68.1bUK£7.9b57.3x32.1x3.7x
Sat, 08 Apr 2023UK£254.7bUK£69.3bUK£6.9b50.5x37.1x3.7x
Mon, 06 Mar 2023UK£238.0bUK£70.5bUK£7.0b50.3x34.2x3.4x
Price to Earnings Ratio

34.2x


Total Market Cap: UK£238.0bTotal Earnings: UK£7.0bTotal Revenue: UK£70.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 26.5x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 23.2x which is lower than its 3-year average PE of 26.5x.
  • The 3-year average PS ratio of 3.4x is lower than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 8.6% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market1.92%
Healthcare-1.65%
Pharma-1.87%
Pharma-1.87%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AGY Allergy TherapeuticsUK£0.1220.0%
+UK£145.8m		76.5%PS13.8x
ANCR Animalcare GroupUK£2.831.8%
+UK£3.5m		24.1%PE65.5x
STX Shield TherapeuticsUK£0.102.6%
+UK£2.7m		203.0%PS3.5x
EAH ECO Animal Health GroupUK£1.070.9%
+UK£677.6k		79.8%PE24x
TLM Talisman MetalsUK£0.107.9%
+UK£464.1k		144.0%PE96.9x

Latest News

HIK
UK£13.73
Hikma Pharmaceuticals
7D
-16.3%
1Y
-37.1%
GSK
UK£21.67
GSK
7D
-2.7%
1Y
48.3%
HLN
UK£3.94
Haleon
7D
-3.2%
1Y
3.1%
EAH
UK£1.07
ECO Animal Health Group
7D
0.9%
1Y
79.8%
TLM
UK£0.10
Talisman Metals
7D
7.9%
1Y
144.0%
N4P
UK£0.0055
N4 Pharma
7D
10.0%
1Y
4.8%
AZN
UK£151.10
AstraZeneca
7D
-1.2%
1Y
25.7%
AGY
UK£0.12
Allergy Therapeutics
7D
20.0%
1Y
76.5%
IMM
UK£0.083
ImmuPharma
7D
1.0%
1Y
117.5%
STX
UK£0.10
Shield Therapeutics
7D
2.6%
1Y
203.0%

STX: Pediatric Expansion And Extended Exclusivity Will Support Future Upside Potential

Analysts have kept their fair value estimate for Shield Therapeutics broadly steady at £0.17 per share, reflecting only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that they see as refinements rather than a change in thesis. What's in the News The FDA approved an extension of the indication for ACCRUFeR (ferric maltol) to treat iron deficiency in adult and pediatric patients 10 years and older, following a priority review supported by a Phase 3 pediatric trial in children from 1 month of age with iron deficiency anemia (Key Developments).
NFX
UK£0.0024
Nuformix
7D
-2.0%
1Y
172.2%
FUM
UK£0.012
Futura Medical
7D
-5.2%
1Y
-91.3%
ANCR
UK£2.83
Animalcare Group
7D
1.8%
1Y
24.1%
POLB
UK£0.045
Poolbeg Pharma
7D
-3.2%
1Y
28.2%